Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 11/20 | 0.57 |
| ▸ | ABL1 | P00519 | 10/20 | 0.57 |
| ▸ | BCR | P11274 | 7/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.57 |
| ▸ | PRKCA | P17252 | 3/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 4/20 | 0.51 |
| ▸ | BMX | P51813 | 2/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903523 | 0.90 | ABL1 (0.62) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4897577 | 0.89 | ABL1 (0.60) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4900131 | 0.86 | PDGFRA (0.77) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4897322 | 0.86 | PDGFRA (0.59) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4903220 | 0.82 | PDGFRA (0.55) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4899291 | 0.79 | ABL1 (0.62) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4903320 | 0.78 | ABL1 (0.61) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4905315 | 0.78 | PDGFRA (0.61) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4891611 | 0.78 | MEN1 (0.60) | ABL1BCRPRKCABTK | |
| SCHEMBL4905638 | 0.77 | PDGFRA (0.67) | PDGFRAABL1BCRPDGFRBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | PDGFRA 2913/4885ABL1 904/4885BCR 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.